Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Plast Reconstr Aesthet Surg ; 74(3): 480-485, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33069605

RESUMO

INTRODUCTION: Contralateral prophylactic mastectomy has the potential to decrease the occurrence of cancer and reduce psychological burden. However, it is known that complications after bilateral mastectomy are higher compared with unilateral mastectomy. Our goal was to evaluate outcomes of immediate breast reconstruction in patients undergoing bilateral mastectomy and to compare complication rates between therapeutic and prophylactic sides. PATIENTS AND METHODS: Electronic medical records of patients with unilateral breast cancer who underwent bilateral mastectomy and immediate reconstruction with expanders were reviewed. Postoperative complications were compared between therapeutic and prophylactic mastectomy sides. RESULTS: Sixty-two patients were analyzed. The overall complication rate after both stages was 23.9% on the therapeutic side and 16.5% on the prophylactic side. Infection was the most common complication on both sides. All infections on the prophylactic mastectomy side were successfully treated with intravenous (IV) antibiotics (salvage rate of 100%), whereas 35.7% of infected tissue expander/implants on the therapeutic mastectomy side were explanted despite treatment. CONCLUSION: Careful counselling of patients undergoing elective contralateral prophylactic mastectomy is essential as complications can develop in either breast after reconstruction.


Assuntos
Antibacterianos/administração & dosagem , Mastectomia , Mastectomia Profilática , Infecções Relacionadas à Prótese , Infecção da Ferida Cirúrgica , Neoplasias Unilaterais da Mama/cirurgia , Administração Intravenosa , Adulto , Aconselhamento Diretivo/métodos , Registros Eletrônicos de Saúde/estatística & dados numéricos , Feminino , Humanos , Mastectomia/efeitos adversos , Mastectomia/métodos , Pessoa de Meia-Idade , Avaliação das Necessidades , Mastectomia Profilática/efeitos adversos , Mastectomia Profilática/métodos , Infecções Relacionadas à Prótese/epidemiologia , Infecções Relacionadas à Prótese/etiologia , Infecções Relacionadas à Prótese/terapia , Medição de Risco/métodos , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/etiologia , Infecção da Ferida Cirúrgica/terapia , Neoplasias Unilaterais da Mama/epidemiologia , Estados Unidos/epidemiologia
2.
Aesthetic Plast Surg ; 42(1): 64-72, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29270693

RESUMO

INTRODUCTION: Removal of tissue expanders (TE) or implants is a dire consequence of breast reconstruction, and has the potential to halt the reconstructive efforts. Our goals were to characterize a cohort of patients with TE/implant removal, to perform a time-based analysis, and to review the bacteriology associated with explanted devices. MATERIALS AND METHODS: Review of a prospectively maintained database was performed to identify patients who underwent TE/implant removal. Patient characteristics, surgical technique, adjuvant therapies, indications, complications, culture results were obtained. Data were analyzed according to timing of explantation. RESULTS: A total of 55 TE and implants were removed in 43 patients. Reasons for explantation were infection (58%), patient request (22%), and wound-related complications (20%). The majority of explantations occurred after 30 days (62%), and after Stage I (81%). Median days to explantation was 62. Patients of older age (p = 0.01) and higher BMI (p = 0.02) were more likely to undergo explantation after Stage I. The most commonly cultured organisms were S. epidermidis (10.9%), S. aureus (10.9%) and P. aeruginosa (10.9%). Antibiotic resistance was commonly encountered for ampicillin, cefazolin, penicillin, and erythromycin. CONCLUSION: Infection is the most common reason for explantation after prosthetic breast reconstruction. Patients should be carefully monitored for a prolonged period of time after Stage I, as the majority of explantations occur in this stage but beyond 30 days. For oral treatment, fluoroquinolones and trimethoprim-sulfamethoxazole and for IV treatment a combination of vancomycin or daptomycin with piperacillin-tazobactam or imipenems/carbapenems appear to be appropriate choices according to our culture results. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .


Assuntos
Implantes de Mama/efeitos adversos , Mamoplastia/métodos , Infecções Relacionadas à Prótese/tratamento farmacológico , Dispositivos para Expansão de Tecidos/efeitos adversos , Adulto , Antibacterianos/uso terapêutico , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Institutos de Câncer , Estudos de Coortes , Bases de Dados Factuais , Remoção de Dispositivo/métodos , Feminino , Seguimentos , Humanos , Mamoplastia/efeitos adversos , Mastectomia/métodos , Pessoa de Meia-Idade , Falha de Prótese , Infecções Relacionadas à Prótese/diagnóstico , Infecções Relacionadas à Prótese/epidemiologia , Reoperação/métodos , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...